ValuEngine downgraded shares of Sevion Therapeutics (OTCMKTS:SVON) from a hold rating to a sell rating in a research report report published on Friday.
Shares of Sevion Therapeutics (OTCMKTS SVON) opened at $0.39 on Friday. Sevion Therapeutics has a twelve month low of $0.13 and a twelve month high of $0.44.
TRADEMARK VIOLATION NOTICE: “Sevion Therapeutics (SVON) Downgraded by ValuEngine” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/12/04/sevion-therapeutics-svon-downgraded-by-valuengine.html.
Sevion Therapeutics, Inc is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Sevion Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sevion Therapeutics Inc and related companies.